Surgical tracheotomy in COVID-19 patients: an Italian single centre experience.
Coronavirus infection disease
Covid-19
Respiratory distress syndrome
SARS-CoV2
Tracheotomy
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
27
12
2020
accepted:
09
02
2021
pubmed:
23
2
2021
medline:
6
10
2021
entrez:
22
2
2021
Statut:
ppublish
Résumé
Coronavirus infection disease 2019 (COVID-19) causes in 10% of patients a severe respiratory distress syndrome managed with invasive mechanical ventilation (IMV), sometimes difficult to wean. The role of tracheotomy is debated for the possible risks for patients and staff. We are going to describe here our experience with surgical tracheotomy in COVID-19 positive patients. We enrolled all intensive care unit (ICU) patients requiring longer than 10 days of IMV. Demographic, clinical, respiratory, complications, and outcomes data were collected, in a particular length of weaning from sedation and IMV, in-ICU and in-hospital mortality rate. All healthcare operators involved were tested for SARS-CoV2 by pharyngeal swab and blood test (antibody test). 13 out of 68 ICU patients (19.1%) underwent surgical tracheotomy after a median intubation period of 14 days. The mean age was 60 (56-65) years. 85% were male patients. Postoperative mild bleeding was seen in 30.7%, pneumothorax in 7.7%. Mean weaning from sedation required 3 days, 19 days from IMV. In-ICU and in-hospital COVID-infection-related mortality was 23.1% and 30.7%, respectively. None of the healthcare operators was found SARS-CoV2 positive during the period of the study. In COVID-19 pandemic surgical tracheotomy enables to wean from sedation and subsequently from IMV in a safe way for both patients and personnel.
Identifiants
pubmed: 33616747
doi: 10.1007/s00405-021-06697-6
pii: 10.1007/s00405-021-06697-6
pmc: PMC7897727
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4501-4507Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Références
Eur Ann Otorhinolaryngol Head Neck Dis. 2020 May;137(3):167-169
pubmed: 32307265
Am J Otolaryngol. 2020 Jul - Aug;41(4):102535
pubmed: 32402693
Lancet Respir Med. 2020 Jul;8(7):717-725
pubmed: 32422180
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
Head Neck. 2020 Jun;42(6):1291-1296
pubmed: 32329926
Otolaryngol Head Neck Surg. 2020 Jul;163(1):135-137
pubmed: 32396455
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 Jul;8(7):656-657
pubmed: 32422179
Eur Arch Otorhinolaryngol. 2021 Feb;278(2):313-321
pubmed: 32556788
Oral Oncol. 2020 Jun;105:104682
pubmed: 32278111
Head Neck. 2020 Jun;42(6):1297-1302
pubmed: 32329922
Ann Thorac Surg. 2020 Sep;110(3):1006-1011
pubmed: 32339508
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2173-2184
pubmed: 32314050
Anaesthesia. 2020 Dec;75(12):1659-1670
pubmed: 32396986
Eur Arch Otorhinolaryngol. 2020 Jul;277(7):2133-2135
pubmed: 32322959
Head Neck. 2020 Jul;42(7):1374-1381
pubmed: 32427403
J Otolaryngol Head Neck Surg. 2020 Apr 27;49(1):23
pubmed: 32340627
Eur Arch Otorhinolaryngol. 2021 Aug;278(8):3119-3123
pubmed: 33388981
Ann Surg. 2020 Jul;272(1):e30-e32
pubmed: 32379079
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2403-2404
pubmed: 32458121
Eur Arch Otorhinolaryngol. 2021 May;278(5):1605-1612
pubmed: 32749607
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632